DK2480655T3 - Cellekulturmedium - Google Patents
Cellekulturmedium Download PDFInfo
- Publication number
- DK2480655T3 DK2480655T3 DK10779041.2T DK10779041T DK2480655T3 DK 2480655 T3 DK2480655 T3 DK 2480655T3 DK 10779041 T DK10779041 T DK 10779041T DK 2480655 T3 DK2480655 T3 DK 2480655T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- cell culture
- culture medium
- blood
- medium
- Prior art date
Links
- 239000006143 cell culture medium Substances 0.000 title claims description 63
- 210000004027 cell Anatomy 0.000 claims description 79
- 210000004369 blood Anatomy 0.000 claims description 58
- 239000008280 blood Substances 0.000 claims description 58
- 239000002609 medium Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 29
- 238000012258 culturing Methods 0.000 claims description 21
- 210000005260 human cell Anatomy 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 239000007858 starting material Substances 0.000 claims description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 8
- 102000001554 Hemoglobins Human genes 0.000 claims description 7
- 108010054147 Hemoglobins Proteins 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 3
- 238000005199 ultracentrifugation Methods 0.000 claims description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 claims 2
- 230000009172 bursting Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 74
- 239000003814 drug Substances 0.000 description 74
- 230000004083 survival effect Effects 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 28
- 230000035945 sensitivity Effects 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 19
- 239000003918 blood extract Substances 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 238000003556 assay Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000009650 gentamicin protection assay Methods 0.000 description 11
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000003239 susceptibility assay Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000002151 Pleural effusion Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010063045 Effusion Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000010420 art technique Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035572 chemosensitivity Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000021049 nutrient content Nutrition 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006786 activation induced cell death Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (11)
1. Cellekulturmedium til dyrkning af humane celler omfattende et anti-koaguleret helblods-materiale af pattedyroprindelse, hvor cellerne til stede i blodet er sprunget og de uopløselige rester fra de lyserede celler er fjernet, ionindholdet af mediet er genoprettet således at det matcher det fra den ekstracellulære fraktion af helblods-udgangsmaterialet, indholdet og/eller sammensætningen af lavmolekylærvægt (< 3000 Dalton) næringsstoffer i det væsentlige er det samme som for et konventionelt cellekulturmedium, reduktionskapaciteten af mediet er genoprettet, og hvor hæmoglobinindholdet er fra 8 til 16 g/dl.
2. Cellekulturmediet ifølge krav 1, hvor blodet er af human oprindelse.
3. Cellekulturmediet ifølge et hvilket som helst af kravene 1 til 2, hvor indholdet og/eller sammensætningen af lavmolekylærvægt (< 3000 Dalton) næringsstoffer i det væsentlige er det samme som for et konventionelt cellekulturmedium er valgt fortrinsvis fra gruppen bestående af RPMI, DMEM, og IMDM.
4. Cellekulturmediet ifølge et hvilket som helst af kravene 1 til 3, hvor reduktionskapaciteten af mediet er genoprettet ved tilsætning af reduceret glutathion.
5. Anvendelse af et cellekulturmedium ifølge et hvilket som helst af kravene 1 til 4 til dyrkning af humane celler.
6. Fremgangsmåde til fremstillingen af et cellekulturmedium til dyrkning af humane celler, omfattende (a) at tilvejebringe anti-koaguleret pattedyrsblod som udgangsmateriale fra en blodprøve; (b) at mekanisk sprænge cellerne der er til stede i blodet; (c) at fjerne de uopløselige rester af de lyserede celler; (d) at genoprette ionindholdet af mediet således at det matcher det fra den ekstracellulære fraktion af helblods-udgangsmaterialet; (e) at justere lavmolekylærvægt (< 3000 Dalton) indholdet og/eller sammensætningen af mediet mod konventionelt cellekulturmedium; og (f) at genoprette reduktionskapaciteten af mediet.
7. Fremgangsmåden ifølge krav 6, hvor den mekaniske sprængning af cellerne opnås ved frysning af helblodet eller ved ultralyd, elektrisk klinge homogenisator eller stempelkande.
8. Fremgangsmåden ifølge krav 6 eller 7, hvor de uopløselige rester fra de lyserede celler fjernes ved ultracentrifugering eller mekanisk filtrering.
9. Fremgangsmåden ifølge et hvilket som helst af kravene 6 til 8, hvor lavmolekylvægt indholdet og/eller sammensætningen justeres ved dialyse, og det konventionelle cellekulturmedium er valgt fortrinsvis fra gruppen bestående af RPMI, DMEM, og IMDM.
10. Fremgangsmåden ifølge et hvilket som helst af kravene 6 til 9, hvor reduktionskapaciteten af mediet genoprettes ved tilsætning af reduceret glutathion.
11. Cellekulturmediet til dyrkning af humane celler, opnået ved fremgangsmåden ifølge et hvilket som helst af kravene 6 til 10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0900603A HUP0900603A2 (en) | 2009-09-25 | 2009-09-25 | Cell culture medium |
| PCT/IB2010/054303 WO2011036637A2 (en) | 2009-09-25 | 2010-09-24 | Cell culture medium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2480655T3 true DK2480655T3 (da) | 2016-04-25 |
Family
ID=89989267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10779041.2T DK2480655T3 (da) | 2009-09-25 | 2010-09-24 | Cellekulturmedium |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9790464B2 (da) |
| EP (1) | EP2480655B8 (da) |
| DK (1) | DK2480655T3 (da) |
| ES (1) | ES2569236T3 (da) |
| HU (1) | HUP0900603A2 (da) |
| PL (1) | PL2480655T3 (da) |
| WO (1) | WO2011036637A2 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016207721A1 (en) | 2015-06-25 | 2016-12-29 | University Of Limerick | Mechanical device for generating combinatorial library |
| CN108884445A (zh) * | 2016-03-09 | 2018-11-23 | 北京智康博药肿瘤医学研究有限公司 | 肿瘤细胞悬浮培养物和相关方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801537D0 (sv) * | 1988-04-26 | 1988-04-26 | Ellco Food Ab | Cellodlingsmedium samt forfarande for dess framstellning |
| GB0108143D0 (en) * | 2001-03-31 | 2001-05-23 | Univ Dundee | High-throughput screen |
| EP1397149A1 (en) * | 2001-06-18 | 2004-03-17 | S.A.V Virex Co Ltd | Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract |
| DE60235835D1 (de) * | 2001-11-30 | 2010-05-12 | Life Technologies Corp | Zellkulturmedien |
| WO2007044427A2 (en) * | 2005-10-05 | 2007-04-19 | Panomics, Inc. | Detection of nucleic acids from whole blood |
| EP2120975B1 (de) | 2006-12-22 | 2015-09-23 | Horst Kief | Vollblutkulturen mit stimulierten immunzellen und deren verwendung als heilmittel |
| EP2427483B1 (en) * | 2009-05-07 | 2015-03-11 | Hemarina | Novel heamoglobin and uses thereof |
-
2009
- 2009-09-25 HU HU0900603A patent/HUP0900603A2/hu unknown
-
2010
- 2010-09-24 US US13/497,707 patent/US9790464B2/en not_active Expired - Fee Related
- 2010-09-24 PL PL10779041.2T patent/PL2480655T3/pl unknown
- 2010-09-24 DK DK10779041.2T patent/DK2480655T3/da active
- 2010-09-24 WO PCT/IB2010/054303 patent/WO2011036637A2/en active Application Filing
- 2010-09-24 ES ES10779041.2T patent/ES2569236T3/es active Active
- 2010-09-24 EP EP10779041.2A patent/EP2480655B8/en not_active Not-in-force
-
2017
- 2017-10-16 US US15/785,011 patent/US20180080006A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011036637A3 (en) | 2011-06-16 |
| EP2480655B1 (en) | 2016-01-27 |
| HUP0900603A2 (en) | 2012-02-28 |
| WO2011036637A2 (en) | 2011-03-31 |
| ES2569236T3 (es) | 2016-05-09 |
| US9790464B2 (en) | 2017-10-17 |
| EP2480655A2 (en) | 2012-08-01 |
| EP2480655B8 (en) | 2016-08-10 |
| HU0900603D0 (en) | 2009-12-28 |
| US20130071925A1 (en) | 2013-03-21 |
| PL2480655T3 (pl) | 2016-10-31 |
| US20180080006A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023521878A (ja) | 食道扁平上皮癌の上皮細胞用の培養培地、培養方法、及びその用途 | |
| CN113755441B (zh) | 一种肺癌微肿瘤细胞模型的培养方法 | |
| JP2002536635A (ja) | 体液から腫瘍細胞を濃縮するか又は除去する方法及びかかる目的に適したキット | |
| US20160369241A1 (en) | Methods of primary tissue culture and drug screening using autologous serum and fluids | |
| WO2015069742A1 (en) | Tissue array for cell spheroids and methods of use | |
| US20180080006A1 (en) | Cell culture medium | |
| CN105939601A (zh) | 在室温稳定全血 | |
| US20180052168A1 (en) | Ex vivo liquid biopsy | |
| CN116421629B (zh) | 干细胞外泌体在预防或治疗衰老的药物中的应用 | |
| AU2016395556B2 (en) | Method for detecting or separating/obtaining circulating tumor cell employing cell proliferation method | |
| Jogalekar et al. | Total RNA isolation from separately established monolayer and hydrogel cultures of human glioblastoma cell line | |
| JP7627064B2 (ja) | 初代消化管間質腫瘍細胞の培養培地、培養方法、及びそれらの利用 | |
| WO2015164560A1 (en) | Intertumoral homogeneity determined by mick assay | |
| Keagle et al. | Basic laboratory procedures | |
| CN102174465A (zh) | 一种从组织中分离富集靶细胞的方法 | |
| CN116519926B (zh) | 肿瘤特异性免疫细胞标志物及其用途 | |
| CN118685360B (zh) | 一种人源去分化脂肪肉瘤细胞系和应用 | |
| CN112126627B (zh) | 一种犬角膜上皮细胞永生化细胞系的构建方法和应用 | |
| US12264305B2 (en) | Devices and methods for isolating a migratory cell population | |
| US20200033345A1 (en) | Method and kit for diagnosis and/or prognosis of non-hematological tumors | |
| Alhalfawy et al. | Stem cell therapy in renal diseases | |
| JP7104930B2 (ja) | 不死化赤血球前駆細胞由来の血球様細胞を用いたマラリア原虫等の維持培養・感染評価に適した細胞の決定方法 | |
| Ekedal | Optimising single-cell gene expression profiling of circulating tumour cells | |
| JP2016106622A (ja) | 細胞の分離回収方法 | |
| Harb et al. | Contribution of electron microscopy of cell cultures to the classification of three round cell sarcomas in children |